摘要
目的:评价bag-1和bcl-2在诊断非小细胞肺癌中的临床价值。方法:采用ELISA法对2007年1月至2010年5月在海口市人民医院心胸外科接受手术治疗经病理组织检查确诊的116例非小细胞肺癌患者(Ⅰ~Ⅱ)和健康体检107例的外周血清进行bag-1、bcl-2蛋白浓度检测。结果:116例非小细胞肺癌患者血清中的bag-1、bcl-2阳性表达率高于107例健康者(P<0.01);诊断非小细胞肺癌,单检bag-1的敏感度、特异度、阳性拟然比分别为65.7%、52.6%、1.40。而bcl-2分别为73.3%、45.8%、1.35;两者联合检测分别是89.7%、95.1%、18.31,都高于单检,有明显差异,有统计学意义(P<0.05)。结论:bag-1和bcl-2在诊断非小细胞肺癌有较高的临床价值。
Objective To evaluate the clinical significance of bag-1 and bcl-2 in the diagnosis of non-small cell lung cancer(NSCLC).Methods The concentrations of bag-1 and bcl-2 in serum in 116 patients with NSCLC(Ⅰ-Ⅱ) determined by pathological examination and 107 healthy controls from January 2007 to May 2010 were measured by ELISA method.Results The levels of bag-1 and bcl-2 in serum in 116 patients with NSCLC were higher than those in healthy controls(P 〈 0.01).The sensitivity,specificity,and positive predictive value of bag-1 or bcl-2 alone for the diagnosis of NSCLC were 65.7%,52.6%,1.40 and 73.3%,45.8%,1.35.And those of the combination of bag-1 and bcl-2 were 89.7%,95.1%,18.31,which were higher than the former two(P 〈 0.05).Conclusion There were higher clinical value of bag-1 and bcl-2 for the diagnosis of NSCLC.
出处
《实用医学杂志》
CAS
北大核心
2012年第20期3372-3374,共3页
The Journal of Practical Medicine